ALK-Abelló A/S

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/07/2026 BST			5-day change	1st Jan Change
240.40 ^DKK	-0.91%		-0.50%	+5.16%

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT

Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026

Published on 05/04/2026 at 11:08 am BST

S&P Capital IQ

Add MarketScreener to your sources

ALK-ABELLÓ A/S

-0.91%

ALK-Abelló A/S upgraded earnings guidance for the full-year 2026. For the year, the company revenue is now expected to grow by 13-16% in local currencies (previously 11-15% growth) based on growth across all sales regions and product lines. The EBIT margin is now expected at around 26% (previously 25%).

Add MarketScreener to your sources

Latest news about ALK-Abelló A/S

06-15	ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis	CI
06-15	UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment	MT
05-28	Berenberg Starts ALK-Abelló at Buy on Growth Potential Amid Food Allergy Market Entry Plans	MT
05-04	ALK-Abelló A/S, Q1 2026 Earnings Call, May 04, 2026
05-04	ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	ALK-Abelló Upgrades FY26 Revenue Outlook	MT
05-04	Alk-Abello Q1 Ebit up at DKK 570 million	RE
05-04	Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026	CI
04-20	ALK-Abelló Reports Positive Results from Mid-stage Trial of Peanut Allergy Treatment	MT
04-20	ALK-Abello announces successful outcome of phase 2 trial of peanut allergy tablet	RE
04-20	ALK Announces Successful Outcome of Phase 2 Trial with Its Tablet for Treatment of Peanut Allergy Demonstrating Early Onset of Efficacy	CI
04-15	ALK-Abelló Receives Approval to Sell Needle-Free Anaphylaxis Treatment in Canada	MT
04-15	Alk-Abello says Neffy approved in Canada	RE
04-15	ALK-Abelló A/S Receives Approval For Neffy 2 Mg As Needle-Free Anaphylaxis Treatment In Canada	CI
03-31	Alk-Abello says EURneffy 1 mg approved across the EU	RE

Chart ALK-Abelló A/S

Duration

Period

ALK B: Dynamic Chart

Company Profile

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâ€™s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Employees

2,759

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company